Form 4: Madrigal Pharmaceuticals Director Receives Stock Grant and Option

Madrigal Pharmaceuticals director Daniel J. Brennan was granted restricted stock units and a stock option, according to a Form 4 filing.

Summary

• Daniel J. Brennan, a Director at Madrigal Pharmaceuticals, Inc., received a grant of 404 shares of Common Stock on June 17, 2026.
• This grant was part of a restricted stock unit award that vests on the earlier of June 17, 2027, or the Issuer's 2027 annual meeting of stockholders, contingent on continued service.
• Additionally, Brennan was granted a stock option to purchase 681 shares of Common Stock at an exercise price of $499.86.
• This option vests 100% on the earlier of June 17, 2027, or the Issuer's 2027 annual meeting of stockholders, also contingent on continued service.
• Following these transactions, Brennan beneficially owns 1,371 shares of Common Stock directly.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it reflects standard compensation practices and insider commitment, but does not contain new financial performance data.

Positives

• Director Daniel J. Brennan received a significant grant of restricted stock units (404 shares) and a stock option (681 shares), indicating continued investment in the company's future by a key insider.
• The vesting schedule for both the RSUs and the stock option is tied to continued service and a future date (June 17, 2027, or the 2027 annual meeting), aligning the director's incentives with long-term company performance.
• The direct beneficial ownership of 1,371 shares post-transaction suggests a substantial personal stake in the company.

Risks

• The vesting of the stock options and RSUs is contingent on the reporting person continuing in service with the Issuer, implying a risk of forfeiture if service is terminated before the vesting date.
• The exercise price of the stock option ($499.86) is a significant hurdle, meaning the stock price would need to appreciate considerably for the option to be profitable.

Future Outlook

The future outlook for the granted securities is tied to the company's performance and the continued service of Daniel J. Brennan, with vesting scheduled for June 17, 2027, or the 2027 annual meeting.

Industry Context

StockSavvy.ai notes that grants of equity awards like restricted stock units and stock options to directors are standard practice in the biopharmaceutical industry to incentivize long-term commitment and align executive interests with shareholder value.

Stakeholder Impact

• Shareholders: The grants align director incentives with long-term shareholder value, potentially leading to better strategic decisions.
• Employees: Standard compensation practice that reinforces the company's ability to attract and retain key talent.
• Management: Reinforces the alignment of management's interests with those of the company and its shareholders.

Next Steps

• Vesting of restricted stock units and stock option on June 17, 2027, or the 2027 annual meeting, provided Daniel J. Brennan continues in service.

Key Dates

Keywords

Madrigal Pharmaceuticals, MDGL, Form 4, Insider Transaction, Stock Grant, Restricted Stock Units, Stock Option, Director Compensation, Beneficial Ownership, SEC Filing